AtriCure Q3 Revenue Up 15% to $154.5M; Full-Year Guidance Set at $606-610M
ATRC has more than doubled off its 52-week low of $25.36.
Summary
AtriCure reported Q3 2026 revenue of $154.5 million (+15.0% year over year), net income of $4.1 million and adjusted EBITDA of $26.8 million, and guided full-year 2026 revenue to about $606-610 million.
Key Events · Earnings and Guidance · ATRC
-
Q3 Revenue Grows 15% to $154.5M
Worldwide revenue of $154.5 million rose 15.0% year over year (15.1% constant currency), with U.S. revenue of $128.0 million up 17.1% on cryoSPHERE MAX, EnCompass and AtriClip FLEX-Mini/PRO-Mini.
-
Profitability Expands Sharply
Gross margin rose 180 basis points to 77.3%, net income was $4.1 million ($0.08 per diluted share) versus a $0.3 million loss a year ago, and adjusted EBITDA climbed 51% to $26.8 million.
-
Full-Year 2026 Guidance Issued
Management projects 2026 revenue of approximately $606-610 million, adjusted EBITDA of $91-94 million, GAAP net income per share of $0.21-0.27 and adjusted EPS of $0.40-0.46, with continued positive cash generation.
-
Minimally Invasive Ablation Declines
Minimally invasive ablation revenue fell to $5.4 million from $7.4 million in the U.S. as physicians adopt PFA catheters and Hybrid procedure volumes shrink — the one segment working against the growth story.
Analysis · ATRC · Industrial Applications And Services
The growth and margin story held together in the third quarter. Revenue of $154.5 million rose 15.0% year over year, gross margin expanded 180 basis points to 77.3%, and adjusted EBITDA jumped 51% to $26.8 million. A $4.1 million net profit replaced a small loss a year ago, and management now guides full-year 2026 revenue to roughly $606-610 million, with adjusted EBITDA of $91-94 million and adjusted EPS of $0.40-0.46. The soft spot is minimally invasive ablation, where sales fell as physicians shift to PFA catheters — a competitive substitution worth tracking against the strength in pain management and appendage management. With the stock near its 52-week high, the print and guidance are the near-term test of whether that valuation holds.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATRC was trading at $60.35 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $25.36 to $63.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.